Catriona Yale

Chief Development Officer

Catriona Yale (Chief Development Officer) filed 15 Form 4 reports in the past 24 months (0 purchases, 15 sales, 4 filed past the two-business-day deadline), most often in AKRO. The largest single filing was $3.0M of AKRO (53,590 sh across 3 lots, as filed), executed Jan 27 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 15 sells · 4 late

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$10.5M

shares × price, as filed

Last traded

Jul 16 2025

Filed Jul 18 2025

Open performance→

Volume by month

Buys $0 Sells $10.5M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Not on file 14 filings

Sector per market data · by filing · past 24 months

Most traded names

AKRO AKRO AKRO · 0 buys · 15 sells 15 filings

Recent filings

AKROSALE Akero Therapeutics, Inc. View filing → $3.0M
53,590 sh across 3 lots
Exec Jan 27 2025
Filed Jan 31 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $264K
9,074 sh × $29.11
Exec Dec 16 2024
Filed Dec 18 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $243K
8,761 sh × $27.69
Exec Nov 15 2024
Filed Nov 19 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $352K
10,000 sh × $35.19
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $652K
20,000 sh across 2 lots
Exec Oct 30 2024
Filed Nov 1 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $627K
20,661 sh across 2 lots
Exec Oct 14 2024
Filed Oct 16 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $152K
5,500 sh × $27.65
Exec Sep 20 2024
Filed Sep 23 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $107K
3,871 sh × $27.56
Exec Sep 18 2024
Filed Sep 18 2024 · 5:30 PM ET